Doyle Wealth Management Biomarin Pharmaceutical Inc Transaction History

Doyle Wealth Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 05, 2019	SELL	$67.4 - $85.11 $20,220 - $25,533	-300 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$80.35 - $93.9 $24,105 - $28,170	300 New	300 $26,000
Q1 2019 May 13, 2019	SELL	$84.2 - $98.62 $25,260 - $29,586	-300 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$80.14 - $106.07 $24,042 - $31,820	300 New	300 $26,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Doyle Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Doyle Wealth Management with notifications on news.